Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends

Diagnostics & Research is Zen Rated C and is the 78th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Dividend Yield	Payout Ratio	Last Dividend	Annual Dividend	Dividend Percentile	Dividend Dropped Count (L10Y)	Ex-dividend Date	Div. Payment Date
SHC	SOTERA HEALTH CO	$4.59B	N/A	0.00%	N/A	N/A	N/A	N/A
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$8.79B	N/A	0.00%	N/A	N/A	N/A	N/A
IDXX	IDEXX LABORATORIES INC	$50.83B	N/A	0.00%	N/A	N/A	N/A	N/A
LH	LABCORP HOLDINGS INC	$23.76B	1.01%	31.50%	$0.7200	$2.88	23%	0	2025-11-26	2025-12-11
A	AGILENT TECHNOLOGIES INC	$40.23B	0.52%	22.90%	$0.2480	$0.74	10%	0		2025-10-22
DHR	DANAHER CORP	$149.70B	0.46%	24.90%	$0.3200	$0.96	9%	2		2025-10-31
EXAS	EXACT SCIENCES CORP	$11.59B	N/A	0.00%	N/A	N/A	N/A	N/A
IQV	IQVIA HOLDINGS INC	$34.77B	N/A	0.00%	N/A	N/A	N/A	N/A
NEOG	NEOGEN CORP	$1.28B	N/A	0.00%	N/A	N/A	N/A	N/A
MEDP	MEDPACE HOLDINGS INC	$14.84B	N/A	0.00%	N/A	N/A	N/A	N/A
QGEN	QIAGEN NV	$10.51B	N/A	0.00%	$1.2800	N/A	N/A	0
TMO	THERMO FISHER SCIENTIFIC INC	$203.50B	0.31%	9.50%	$0.4300	$1.68	4%	0
RDNT	RADNET INC	$5.92B	N/A	0.00%	N/A	N/A	N/A	N/A
FLGT	FULGENT GENETICS INC	$694.21M	N/A	0.00%	N/A	N/A	N/A	N/A
DGX	QUEST DIAGNOSTICS INC	$21.19B	0.84%	36.60%	$0.8000	$1.60	19%	0		2025-10-20
MYGN	MYRIAD GENETICS INC	$725.75M	N/A	0.00%	N/A	N/A	N/A	N/A
MTD	METTLER TOLEDO INTERNATIONAL INC	$27.79B	N/A	0.00%	N/A	N/A	N/A	N/A
ILMN	ILLUMINA INC	$14.67B	N/A	0.00%	N/A	N/A	N/A	N/A
WAT	WATERS CORP	$19.92B	N/A	0.00%	N/A	N/A	N/A	N/A
XGN	EXAGEN INC	$253.92M	N/A	0.00%	N/A	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$198.71M	N/A	0.00%	N/A	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$1.70B	N/A	0.00%	N/A	N/A	N/A	N/A
RVTY	REVVITY INC	$10.84B	0.15%	11.90%	$0.0700	$0.14	1%	0		2025-11-07
NEO	NEOGENOMICS INC	$1.30B	N/A	0.00%	N/A	N/A	N/A	N/A
PRPH	PROPHASE LABS INC	$20.77M	N/A	0.00%	$0.3000	N/A	N/A	0
MDXH	MDXHEALTH SA	$19.85M	N/A	0.00%	N/A	N/A	N/A	N/A
GRAL	GRAIL INC	$2.81B	N/A	0.00%	N/A	N/A	N/A	N/A
ICLR	ICON PLC	$14.39B	N/A	0.00%	N/A	N/A	N/A	N/A
CSTL	CASTLE BIOSCIENCES INC	$642.24M	N/A	0.00%	N/A	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$8.16B	N/A	0.00%	N/A	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$205.73M	N/A	0.00%	N/A	N/A	N/A	N/A
NTRA	NATERA INC	$24.81B	N/A	0.00%	N/A	N/A	N/A	N/A
NOTV	INOTIV INC	$45.35M	N/A	0.00%	N/A	N/A	N/A	N/A
PSNL	PERSONALIS INC	$809.62M	N/A	0.00%	N/A	N/A	N/A	N/A
STIM	NEURONETICS INC	$177.88M	N/A	0.00%	N/A	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$485.13M	N/A	0.00%	N/A	N/A	N/A	N/A
CDNA	CAREDX INC	$767.00M	N/A	0.00%	N/A	N/A	N/A	N/A
CAI	CARIS LIFE SCIENCES INC	$8.86B	N/A	N/A	N/A	N/A	N/A	N/A
SERA	SERA PROGNOSTICS INC	$121.80M	N/A	0.00%	N/A	N/A	N/A	N/A
DRIO	DARIOHEALTH CORP	$29.64M	N/A	0.00%	N/A	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$4.10M	N/A	0.00%	N/A	N/A	N/A	N/A
BDSX	BIODESIX INC	$47.07M	N/A	0.00%	N/A	N/A	N/A	N/A
OPK	OPKO HEALTH INC	$1.21B	N/A	0.00%	N/A	N/A	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$2.79M	N/A	0.00%	N/A	N/A	N/A	N/A
BNBX	APPLIED DNA SCIENCES INC	$4.48M	N/A	0.00%	N/A	N/A	N/A	N/A
FONR	FONAR CORP	$102.08M	N/A	0.00%	N/A	N/A	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$4.61M	N/A	0.00%	N/A	N/A	N/A	N/A
MYNZ	MAINZ BIOMED NV	$6.10M	N/A	0.00%	N/A	N/A	N/A	N/A
PRPO	PRECIPIO INC	$27.94M	N/A	0.00%	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$17.78M	N/A	0.00%	N/A	N/A	N/A	N/A
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$151.54M	N/A	0.00%	N/A	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$47.77M	N/A	0.00%	N/A	N/A	N/A	N/A
CHEK	CHECK-CAP LTD	$10.65M	N/A	0.00%	N/A	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$86.58M	N/A	0.00%	N/A	N/A	N/A	N/A
XWEL	XWELL INC	$5.73M	N/A	0.00%	N/A	N/A	N/A	N/A
ADVB	ADVANCED BIOMED INC	$10.39M	N/A	0.00%	N/A	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Oct 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: A, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 20, which is -6 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 7 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock return 2.47% over the past year, overperforming other diagnostic & research stocks by 4 percentage points.

Sotera Health Co has an average 1 year price target of $16.33, an upside of 1.07% from Sotera Health Co's current stock price of $16.16.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sotera Health Co, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International (NYSE:CRL) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Charles River Laboratories International (NYSE:CRL) is: Value: C, Growth: B, Momentum: D, Sentiment: B, Safety: B, Financials: B, and AI: B.

Charles River Laboratories International (NYSE:CRL) has a Due Diligence Score of 14, which is -12 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates CRL as a "B".

CRL passed 4 out of 33 due diligence checks and has weak fundamentals. Charles River Laboratories International has seen its stock lose -9.74% over the past year, underperforming other diagnostic & research stocks by -8 percentage points.

Charles River Laboratories International has an average 1 year price target of $180.75, an upside of 1.25% from Charles River Laboratories International's current stock price of $178.52.

Charles River Laboratories International stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Charles River Laboratories International, 50% have issued a Strong Buy rating, 12.5% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: A, and AI: C.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 38.13% over the past year, overperforming other diagnostic & research stocks by 40 percentage points.

Idexx Laboratories has an average 1 year price target of $639.29, an upside of 0.61% from Idexx Laboratories's current stock price of $635.40.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Idexx Laboratories, 28.57% have issued a Strong Buy rating, 14.29% have issued a Buy, 57.14% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.01%, which is the same as the diagnostic & research industry average of 0.55%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 31.5% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 0.84%, which is the same as the diagnostic & research industry average of 0.55%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.6% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.52%, which is the same as the diagnostic & research industry average of 0.55%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.38% in the last day, and up 4.03% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 29 points higher than the diagnostic & research industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has dropped -37.32% in the past year. It has underperformed other stocks in the diagnostic & research industry by -36 percentage points.

2. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Illumina has a valuation score of 29, which is 15 points higher than the diagnostic & research industry average of 14. It passed 2 out of 7 valuation due diligence checks.

Illumina's stock has dropped -33.49% in the past year. It has underperformed other stocks in the diagnostic & research industry by -32 percentage points.

3. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 29, which is 15 points higher than the diagnostic & research industry average of 14. It passed 2 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 13.07% in the past year. It has overperformed other stocks in the diagnostic & research industry by 15 percentage points.

Are diagnostic & research stocks a good buy now?

52.5% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 4.86% over the next year.

2.22% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 13.33% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 11.11% are rated D (Sell), and 6.67% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 22.55x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.